Retatrutide, sammenfatning af evidensgrundlaget Vi ved: Fase 2 viser 24,2% vgttab ved 12 mg over 48 uger (NEJM 2023) Fase 3 TRIUMPH-1, det pivotale fedme-studie (2.339 deltagere), viser 28,3% over 80 uger, op til 30,3% ved 104-ugers forlngelse hos BMI35 (forr 2026) Fase 3 TRIUMPH-4 (knartrose-substudie) viser 28,7% over 68 uger (december 2025) Bivirkningsprofilen ligner semaglutide og tirzepatide Leverfedtreduktion p op til 82% i substudie Markant HbA1c-reduktion ved type 2-diabetes (Lancet 2023) Vi ved endnu ikke: Langsigtet sikkerhed ud over 68 uger Prcis effekt p muskelmasse Kardiovaskulrt outcome (TRIUMPH-3 afventer) Effekt ved ophr Endelig pris og tilskudsstatus i Danmark Retatrutide og mental sundhed, en overset dimension Fedme og mental sundhed er tt forbundne
However, it is critically important to state clearly: there is no peer-reviewed clinical evidence supporting the safety or efficacy of stacking retatrutide with any other peptide
Also showed significant reductions in liver fat (up to 82.4%) and improvements in metabolic parameters Phase 3 (TRIUMPH-4) : The Phase 3 TRIUMPH-4 trial confirmed and exceeded Phase 2 results, demonstrating 28.7% mean weight loss at 68 weeks with the 12 mg dose -- the highest reported for any metabolic peptide in a Phase 3 trial Phase 3 program : Additional Phase 3 trials ongoing for obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) MASLD/MASH : Specific trials underway evaluating liver-related endpoints Phase 3 TRIUMPH-4 data have confirmed the Phase 2 promise, though the full Phase 3 program across all indications is still ongoing
Dietary Intake by Patients Taking GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Narrative Review and Discussion of Research Needs. Obesity Pillars, vol
Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
